Compare AMCR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCR | PODD |
|---|---|---|
| Founded | 1926 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | AMCR | PODD |
|---|---|---|
| Price | $43.28 | $237.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 20 |
| Target Price | $53.67 | ★ $358.00 |
| AVG Volume (30 Days) | ★ 4.7M | 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $56.27 | $24.33 |
| Revenue Next Year | $1.47 | $19.33 |
| P/E Ratio | ★ $33.69 | $69.44 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $7.67 | $230.08 |
| 52 Week High | $50.94 | $354.88 |
| Indicator | AMCR | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 36.55 |
| Support Level | $8.45 | N/A |
| Resistance Level | $45.49 | $299.75 |
| Average True Range (ATR) | 1.09 | 8.38 |
| MACD | -1.75 | 0.50 |
| Stochastic Oscillator | 8.67 | 10.26 |
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.